By Gary M. White, MD

Note, this is a brief summary only. More complete information and recent studies should be consulted before prescribing.

Eucrisa (Anacor Pharmaceuticals, 2% crisaborole ointment) is FDA-approved to treat mild to moderate eczema in patients two-years-of-age and older. It is applied twice daily and may be applied to any skin including the face.

Crisaborole is a small compound that effectively penetrates the skin to inhibit PDE4. Phosphodiesterase 4 (PDE4) is a key regulator of inflammatory cytokine production in AD. PDE4 activity is increased in circulating inflammatory cells of patients with AD and the inhibition of PDE4 in monocytes in vitro has demonstrated reduction in the release of proinflammatory cytokines.

Clinical Practice

Crisaborole competes in the same arena as the calcineuron inhibitors, pimecrolimus and tacrolimus. Crisaborole competes well with TCIs if you look at percent of patients with AD who are clear or almost clear. It also seems to have fewer side effects (e.g. skin burning or itch) compared with the TCIs.


1 year safety data is available and favorable.


JAAD 2016;75;494–503


Homepage | FAQs | Use of Images | Contact Dr. White


Home | FAQs | Use of Images | Privacy Policy | Contact

It is not the intention of to provide specific medical advice, diagnosis or treatment. only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.